Does CYP2C19*17 carrier status affect platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement?
Patients with coronary stent placement treated with clopidogrel
CYP2C19*17 carrier status
Platelet aggregation, bleeding events, and stent thrombosissafety
The CYP2C19*17 allelic variant identifies patients at an increased risk of bleeding and enhanced pharmacodynamic response when treated with clopidogrel after coronary stenting.
CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding.
Building similarity graph...
Analyzing shared references across papers
Loading...
Dirk Sibbing
Interventional Cardiology
Werner Koch
Goethe University Frankfurt
Daniela Gebhard
Klinikum rechts der Isar
Circulation
Klinikum rechts der Isar
Building similarity graph...
Analyzing shared references across papers
Loading...
Sibbing et al. (Tue,) studied this question.
synapsesocial.com/papers/69d5707a75589c71d767dc5a — DOI: https://doi.org/10.1161/circulationaha.109.885194